NRG/GOG 186K: A randomized phase II study of NCI-supplied cabozantinib versus weekly paclitaxel in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer—Final results

Abstract

Peer reviewed

U.A. Matulonis, M. Sill, P.H. Thaker, J.W. Carlson, C.J. Darus, R.S. Mannel, D.P. Bender, R.V. Higgins and C. Aghajanian

Gynecologic oncology, Vol.141, pp.207-207

06/2016

DOI: 10.1016/j.ygyno.2016.04.533

View Online

Title: Subtitle: NRG/GOG 186K: A randomized phase II study of NCI-supplied cabozantinib versus weekly paclitaxel in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer—Final results
Creators: U.A. Matulonis - Dana-Farber Cancer Institute, Boston, MA, USA
M. Sill - Gynecologic Oncology Group Statistical and Data Center, Buffalo, NY, USA
P.H. Thaker - Washington University School of Medicine in St. Louis, St. Louis, MO, USA
J.W. Carlson - Mercy Clinic - Women's Oncology, Springfield, MO, USA
C.J. Darus - Maine Medical Partners, Scarborough, ME, USA
R.S. Mannel - University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
D.P. Bender - University of Iowa
R.V. Higgins - Levine Cancer Institute, Carolinas Medical Center, Charlotte, NC, USA
C. Aghajanian - Memorial Sloan Kettering Cancer Center, New York, NY, USA
Resource Type: Abstract
Publication Details: Gynecologic oncology, Vol.141, pp.207-207
Publisher: Elsevier Inc
DOI: 10.1016/j.ygyno.2016.04.533
ISSN: 0090-8258
eISSN: 1095-6859
Language: English
Date published: 06/2016
Academic Unit: Obstetrics and Gynecology
Record Identifier: 9984317107502771

8 Record Views